Affinity DataKd: 0.0700nMAssay Description:Binding affinity to Keap1 (unknown origin) by SPR assayMore data for this Ligand-Target Pair
Affinity DataKi: <0.100nMAssay Description:Inhibition of Keap1-Nrf2 protein-protein interaction (unknown origin) preincubated for 30 mins followed by Terbium labeled anti-His antibody addition...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.140nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
Affinity DataIC50: 0.140nMAssay Description:Inhibition of FITC-9mer Nrf2 peptide interaction with human recombinant Keap1 Kelch domain (321 to 609 residues) expressed in Escherichia coli DE3 ce...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.150nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.150nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.170nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.170nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.170nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.190nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.200nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.200nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.200nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.230nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.230nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.240nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.25nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.25nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.260nMAssay Description:Fluorescence polarization assay was performed on a Wallac Victor 3V multi-label counter/plate reader (PerkinElmer, Shelton, CT) using 484 nm excitati...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.270nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.270nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.280nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.300nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.300nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.310nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.350nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.350nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.350nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.350nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.350nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.360nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.360nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.390nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.390nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.410nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.410nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.450nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.5nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.530nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.550nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
Affinity DataKd: 0.700nMAssay Description:Binding affinity to Keap1 (unknown origin) by SPR assayMore data for this Ligand-Target Pair
Affinity DataKd: 0.700nMAssay Description:Binding affinity to Keap1 kelch domain (unknown origin) by surface plasmon resonance assayMore data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.710nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
Affinity DataKd: 0.880nMAssay Description:Binding affinity to Keap1 (unknown origin) by SPR assayMore data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.890nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.900nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair
Affinity DataKi: 1nMAssay Description:Inhibition of Cys5-LDEETGEFL-NH2 binding to recombinant human KEAP1 Kelch domain (321 to 609 residues) expressed in Escherichia coli BL21 (DE3) measu...More data for this Ligand-Target Pair
Affinity DataKd: 1nMAssay Description:Binding affinity to biotinylated Keap1 Kelch domain (unknown origin) by SPR methodMore data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.01nMAssay Description:The inhibitory activity of each compound on the binding between NRF2 and KEAP1 was measured by bioluminescence resonance energy transfer (BRET) assay...More data for this Ligand-Target Pair
TargetKelch-like ECH-associated protein 1/Nuclear factor erythroid 2-related factor 2(Human)
Senju Pharmaceutical Co.
US Patent
Senju Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.05nMAssay Description:In a first step, the Keapl /compound complex was prepared by addition of 100 nL of the compound by ECHO 555, followed by 5 pL aliquots of 2x Keapl. T...More data for this Ligand-Target Pair




3D Structure (crystal)









































